SEC Filings
Teva's Research And Medical Chief Leaves His Role After Accepting An Outside Offer
Teva kept its $6–7 billion innovative-medicines revenue ambition for 2030 as it began searching for a permanent successor.
Teva Pharmaceutical Industries (TEVA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Teva kept its $6–7 billion innovative-medicines revenue ambition for 2030 as it began searching for a permanent successor.
SEC Filings
Three branded drugs grew 33% in local currency to about $1.1 billion, offsetting a 2% revenue dip from generic lenalidomide competition.